Small Pharma Receives Approval for First-In-Human Phase I Clinical Trial With SPL028 Post published:October 31, 2022 Post category:Press Release
ENOSIS THERAPEUTICS AND OVID CLINICS ANNOUNCE PARTNERSHIP TO LAUNCH WORLD’S FIRST IN-CLINIC APPLICATION OF VIRTUAL REALITY MODULATED PSYCHEDELIC-AUGMENTED PSYCHOTHERAPY Post published:October 31, 2022 Post category:Press Release
Psychedelic Bulletin #121: The State of Psychedelic Economy and Industry; Dispatch from Horizons New York 2022 Post published:October 28, 2022 Post category:Psychedelic Bulletin
Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness Post published:October 28, 2022 Post category:Press Release
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022 Post published:October 28, 2022 Post category:Press Release
HAVN Life Announces Retail Listing With Loblaws Company Ltd. Post published:October 28, 2022 Post category:Press Release
Mindset Pharma Announces Poster Presentations at Two Upcoming Scientific Conferences Post published:October 28, 2022 Post category:Press Release
MINDCURE Announces Financial Results for the First Quarter of Fiscal 2023 USA – English USA – English Post published:October 27, 2022 Post category:Press Release
Silo Pharma to Discuss Mainstream Pharma and Psychedelics at Wonderland Miami Conference Post published:October 26, 2022 Post category:Press Release
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression Post published:October 25, 2022 Post category:Press Release